Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
J Pediatr ; 220: 101-108.e2, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32044100

RESUMEN

OBJECTIVES: To evaluate the clinical impact of a congenital adrenal hyperplasia (CAH) newborn screening program and incremental costs relative to benefits in screened vs unscreened infants. We hypothesized that screening would lead to clinical benefits and would be cost effective. STUDY DESIGN: This was an ambispective cohort study at British Columbia Children's Hospital, including infants diagnosed with CAH from 1988-2008 and 2010-2018. Data were collected retrospectively (unscreened cohort) and prospectively (screened cohort). Outcome measures included hospitalization, medical transport, and resuscitation requirements. The economic analysis was performed using a public payer perspective. RESULTS: Forty unscreened and 17 screened infants were diagnosed with CAH (47% vs 53% male). Median days to positive screen was 6 and age at diagnosis was 5 days (range, 0-30 days) and 6 days (range, 0-13 days) in unscreened and screened populations, respectively. In unscreened newborns, 55% required transport to a tertiary care hospital, 85% required hospitalization, and 35% required a fluid bolus compared with 29%, 29%, and 12% in screened infants, respectively. The cost of care was $33 770 per case in unscreened vs $17 726 in screened newborns. In the screened cohort, the incremental cost-effectiveness ratio was $290 in the best case analysis and $4786 in the base case analysis, per hospital day avoided. CONCLUSIONS: Compared with unscreened newborns, those screened for CAH were less likely to require medical transport and had shorter hospital stays. Screening led to a decrease in hospitalization costs. Although screening did not result in cost savings, it was assessed to be cost effective considering the clinical benefits and incremental cost-effectiveness ratio.


Asunto(s)
Hiperplasia Suprarrenal Congénita/diagnóstico , Hiperplasia Suprarrenal Congénita/economía , Tamizaje Neonatal/economía , Colombia Británica , Estudios de Cohortes , Análisis Costo-Beneficio , Femenino , Fluidoterapia/estadística & datos numéricos , Hospitalización/economía , Hospitalización/estadística & datos numéricos , Humanos , Recién Nacido , Tiempo de Internación/estadística & datos numéricos , Masculino , Transporte de Pacientes/estadística & datos numéricos
2.
J Clin Endocrinol Metab ; 103(11): 4043-4088, 2018 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-30272171

RESUMEN

Objective: To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010. Conclusions: The writing committee presents updated best practice guidelines for the clinical management of congenital adrenal hyperplasia based on published evidence and expert opinion with added considerations for patient safety, quality of life, cost, and utilization.


Asunto(s)
Hiperplasia Suprarrenal Congénita/terapia , Endocrinología/normas , Sociedades Médicas/normas , Hiperplasia Suprarrenal Congénita/diagnóstico , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/genética , Análisis Costo-Beneficio , Femenino , Terapias Fetales/economía , Terapias Fetales/métodos , Terapias Fetales/normas , Asesoramiento Genético/economía , Asesoramiento Genético/métodos , Asesoramiento Genético/normas , Glucocorticoides/uso terapéutico , Humanos , Recién Nacido , Cuidados a Largo Plazo/economía , Cuidados a Largo Plazo/métodos , Cuidados a Largo Plazo/normas , Tamizaje Neonatal/economía , Tamizaje Neonatal/normas , Seguridad del Paciente/normas , Calidad de Vida , Terapias en Investigación/economía , Terapias en Investigación/métodos , Terapias en Investigación/normas
3.
Eur J Endocrinol ; 178(4): 309-320, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29371334

RESUMEN

OBJECTIVES: To evaluate the risks of depression and all-cause mortality, healthcare utilisation costs and treatment adherence in congenital adrenal hyperplasia (CAH) in the United Kingdom. DESIGN AND METHODS: A retrospective, matched-cohort study using UK primary-care data from the Clinical Practice Research Datalink linked to hospital and death certification data. Patients diagnosed with CAH and having ≥1 corticosteroid prescription were matched 1:10 to reference subjects. Risk of death and lifetime prevalence of depression were compared using Cox regression models. Direct financial costs were estimated for healthcare contacts. Treatment adherence was measured by medical possession ratio (MPR). RESULTS: 605 patients with CAH were identified; 562 were matched. 270 CAH patients (2700 controls) were linkable to death-certificate data, with adjusted hazard ratio for all-cause mortality 5.17 (95% CI 2.81-9.50). Mean (s.d.) age at death in CAH patients was 54.8 (23.9) vs 72.8 (18.0) years in control patients. The prevalence ratio of depression in CAH vs control patients was 1.28 (95% CI 1.13-1.45). Mean (s.d.) annual healthcare costs were higher in CAH than controls: at age 0-6 years, £7038 (£14 846) vs £2879 (£13 972, P < 0.001); 7-17 years, £3766 (£7494) vs £1232 (£2451, P < 0.001); 18-40 years, £1539 (£872) vs £1344 (£1620, P = 0.007) and ≥41 years, £4204 (£4863) vs £1651 (£2303, P < 0.001). Treatment adherence was lowest in adults, with 141 (36%) of 396 eligible patients having an MPR <80%. CONCLUSIONS: This first analysis of CAH in routine UK healthcare suggests that patients with CAH have increased mortality, depression and healthcare utilisation and low treatment adherence.


Asunto(s)
Hiperplasia Suprarrenal Congénita/complicaciones , Depresión/etiología , Costos de la Atención en Salud/estadística & datos numéricos , Cooperación del Paciente/estadística & datos numéricos , Adolescente , Corticoesteroides/uso terapéutico , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/mortalidad , Adulto , Factores de Edad , Anciano , Niño , Preescolar , Depresión/epidemiología , Depresión/psicología , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Prevalencia , Atención Primaria de Salud/economía , Atención Primaria de Salud/estadística & datos numéricos , Estudios Retrospectivos , Medición de Riesgo , Reino Unido/epidemiología , Adulto Joven
4.
Horm Res Paediatr ; 84(5): 311-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26397944

RESUMEN

BACKGROUND/AIMS: Newborn screening for congenital adrenal hyperplasia (CAH) is generally performed using 17- hydroxyprogesterone dissociation-enhanced, lanthanide fluorescence immunoassay (DELFIA®). The primary screening results must be confirmed due to high false-positive rates; however, the need to obtain a separate specimen can hamper early recognition, differential diagnosis and treatment. We aimed to develop a single liquid chromatography-tandem mass spectrometry (LC-MS/MS) method that allows both the confirmation and differential diagnosis of CAH using the same dried blood spot (DBS) as in primary screening. METHODS: An LC-MS/MS assay for cortisol, 21-deoxycortisol, 11-deoxycortisol, 4-androstenedione and 17-hydroxyprogesterone was developed, validated and applied to a total of 163 DBS samples tested positive in primary newborn screening in a cross-border cooperation. RESULTS: Excellent baseline resolution and reliable determination of all analytes were achieved in DBS samples following simple sample preparation without derivatization. Of a total of 163 DBS samples tested positive in primary screening, the 21-hydroxylase-deficient form of CAH was confirmed in 1 sample. CONCLUSIONS: The present LC-MS/MS assay was successfully applied as a second-tier test in a cross-border cooperation for newborn screening. The assay allows concurrent confirmation and differential diagnosis of CAH and can be performed on the same DBS samples as in primary screening, enabling early diagnosis and treatment.


Asunto(s)
Hiperplasia Suprarrenal Congénita/sangre , Hiperplasia Suprarrenal Congénita/diagnóstico , Pruebas con Sangre Seca/métodos , Tamizaje Neonatal/métodos , Hiperplasia Suprarrenal Congénita/economía , Cromatografía Líquida de Alta Presión , Pruebas con Sangre Seca/economía , Reacciones Falso Positivas , Femenino , Humanos , Hungría , Recién Nacido , Cooperación Internacional , Masculino , Espectrometría de Masas , Tamizaje Neonatal/economía , Control de Calidad , Estándares de Referencia , Reproducibilidad de los Resultados , Rumanía , Esteroide 21-Hidroxilasa/sangre
5.
J Clin Endocrinol Metab ; 100(3): 1002-8, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25494862

RESUMEN

OBJECTIVE: The objective of the study was to evaluate the efficacy of national newborn screening for severe congenital adrenal hyperplasia (CAH) in New Zealand over the past 20 years. METHODS: Newborn screening for CAH is performed through the estimation of 17-hydroxyprogesterone by a Delfia immunoassay. CAH cases diagnosed in the newborn period from 1994 to 2013 were identified from Newborn Metabolic Screening Programme records. RESULTS: Between 1994 and 2013, 44 neonates (28 females, 16 males) were diagnosed with CAH, giving an incidence of 1:26 727. Almost half (n = 21) of the newborns with CAH were detected solely via screening (not clinically suspected), including 21% of all affected females. Among the group solely ascertained by screening, 17-hydroxyprogesterone sampling occurred at a mean age of 3.3 days (range 2-8 d), the duration from sampling to notification was 5.2 days (0-12 d), and treatment was initiated at 12.0 days (6-122 d). Vomiting was present in 14% of those ascertained by screening, but none had hypotension or collapse at diagnosis. Increasing age at treatment was correlated with a progressive decrease in serum sodium (r = -0.56; P < .0001) and an increase in serum potassium concentrations (r = 0.38; P = .017). Compared with newborns diagnosed by screening alone, those clinically diagnosed were predominantly female (96% vs 29%; P < .0001), notification occurred earlier (4.8 vs 8.5 d; P = .002), and had higher serum sodium (136.8 vs 130.8 mmol/L; P < .0001) and lower serum potassium (5.3 vs 6.0 mmol/L; P = .011) concentrations. CONCLUSIONS: Screening alone accounted for nearly 50% cases of CAH detected in the newborn period, including a fifth of affected females, indicating that clinical diagnosis is unreliable in both genders. Symptoms were mild at diagnosis and there were no adrenal crises. This study confirms the benefits of newborn CAH screening.


Asunto(s)
Hiperplasia Suprarrenal Congénita/diagnóstico , Tamizaje Neonatal , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/epidemiología , Análisis Costo-Beneficio , Femenino , Edad Gestacional , Humanos , Incidencia , Recién Nacido , Masculino , Tamizaje Neonatal/economía , Tamizaje Neonatal/normas , Nueva Zelanda/epidemiología , Evaluación de Programas y Proyectos de Salud
7.
J Pediatr Endocrinol Metab ; 19(10): 1207-23, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17172082

RESUMEN

OBJECTIVE: Congenital adrenal hyperplasia (CAH) has the potential to place an enormous burden on families in resource-poor countries, and the aim of this survey was to provide more specific insights into the difficulties faced by families living with CAH in Vietnam. It is hoped that this information will be used to ensure that future efforts to reduce the burden of CAH are as effective, sustainable and appropriate as possible. DESIGN AND METHODS: A questionnaire-based needs assessment survey was offered to parents of children with CAH who were attending the Annual CAH Support Group Meeting held at the National Hospital of Pediatrics (NHP) in Hanoi, Vietnam, on 10th June 2005. RESULTS: Fifty-three families responded to the questionnaire. Information pertaining to the purchase and use of medication to treat CAH, access to medical care, surgical treatment for girls, and a wide range of parental concerns was collected. CONCLUSIONS: This survey highlights the heavy burden that CAH places on families in Vietnam, and provides significant insights into various initiatives that could well help ease this suffering. In particular, efforts must be made to ensure essential medication is affordably available, communication of important messages to parents is enhanced, local support groups encouraged, and early diagnosis and medical treatment of CAH optimized so as to reduce morbidity and mortality.


Asunto(s)
Hiperplasia Suprarrenal Congénita , Pobreza , Adolescente , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/epidemiología , Hiperplasia Suprarrenal Congénita/terapia , Niño , Preescolar , Femenino , Fludrocortisona/uso terapéutico , Humanos , Hidrocortisona/uso terapéutico , Lactante , Recién Nacido , Masculino , Padres , Prednisolona/uso terapéutico , Encuestas y Cuestionarios , Vietnam/epidemiología
9.
Eur J Pediatr ; 162(12): 844-9, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14648216

RESUMEN

UNLABELLED: The aim of this study was to assess the effectivity of the identification of patients with congenital adrenal hyperplasia (CAH) in Hungary in the absence of systematic neonatal screening and to estimate the incidence. Dried blood-spot samples of patients clinically suspected at any age to have CAH were collected between 1978 and 1998 throughout the whole country. 17-Hydroxyprogesterone (17-OHP) was measured by radioimmunoassay. Age-specific cut-offs were used. The effectivity of the system was retrospectively assessed. Additional cases were sought to assess the overall incidence of CAH in Hungary. Among the 1,837 patients investigated, 185 cases of CAH were identified. The overall effectivity was 94.7%. The sensitivity and the specificity were 98.9% and 94.2%, respectively. Salt-wasting (SW) boys were, on average, diagnosed 2 weeks later than SW girls, while both boys and girls with the simple virilising (SV) form were diagnosed at similar ages (2 versus 2.5 years). An additional 19 cases were diagnosed during the study period using other methods (plasma and urinary steroid profiles without blood-spot 17-OHP measurements). The incidence of classical CAH in Hungary was 1:14,300 (CI 95% between 1:12,450 and 1:16,795). Presuming that the incidence of CAH is the same among boys and girls, one can calculate that the diagnosis was missed in 24 boys (2 SW, 22 SV). CONCLUSION: it is possible to identify the vast majority of classical cases of congenital adrenal hyperplasia without a neonatal mass screening programme. However, a significant number of boys with the simple virilising form missed whereas both salt-wasting boys and girls are diagnosed safely.


Asunto(s)
17-alfa-Hidroxiprogesterona/sangre , Hiperplasia Suprarrenal Congénita/diagnóstico , Adolescente , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/epidemiología , Biomarcadores , Niño , Preescolar , Análisis Costo-Beneficio , Femenino , Humanos , Hungría/epidemiología , Incidencia , Lactante , Recién Nacido , Masculino , Radioinmunoensayo , Estudios Retrospectivos , Sensibilidad y Especificidad
10.
Horm Res ; 55(4): 206-11, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11598376

RESUMEN

Neonatal screening for congenital hypothyroidism has been effective in early detection and treatment of the condition. The position with respect to neonatal screening for congenital adrenal hyperplasia has been debated for many years. Some countries have performed congenital adrenal hyperplasia screening for many years, others have conducted pilot studies that were then not adopted. This article endeavours to summarize the complex issues behind decisions whether to screen or not and summarizes the findings of neonatal congenital adrenal hyperplasia screening programmes.


Asunto(s)
Hiperplasia Suprarrenal Congénita , Hiperplasia Suprarrenal Congénita/diagnóstico , Tamizaje Neonatal/métodos , Hiperplasia Suprarrenal Congénita/sangre , Hiperplasia Suprarrenal Congénita/economía , Análisis Costo-Beneficio , Francia , Humanos , Recién Nacido , Tamizaje Neonatal/economía , Tamizaje Neonatal/normas , Guías de Práctica Clínica como Asunto/normas , Esteroide 21-Hidroxilasa/sangre , Suecia
12.
Rev Med Liege ; 53(5): 311-5, 1998 May.
Artículo en Francés | MEDLINE | ID: mdl-9689890

RESUMEN

Systematic neonatal screening offers many advantages for the patients, its family and the community. The Genetic center of the University Hospital of Liège provides neonatal screening for the following diseases: phenylketonuria, congenital hypothyroidy, cystic fibrosis, alpha-1-antitrypsin, adrenal hyperplasia and biotinidase deficiency. On economical grounds, it is clear that the organisation of neonatal screening costs less to the community than the cost of the disease if diagnosis is made too late as to allow an alleviation, or even a total recovery, of the symptomatology.


Asunto(s)
Economía Farmacéutica , Tamizaje Neonatal/economía , Aciltransferasas/deficiencia , Hiperplasia Suprarrenal Congénita/economía , Hiperplasia Suprarrenal Congénita/prevención & control , Amidohidrolasas/deficiencia , Biotinidasa , Hipotiroidismo Congénito , Costo de Enfermedad , Fibrosis Quística/economía , Fibrosis Quística/prevención & control , Costos de la Atención en Salud , Humanos , Hipotiroidismo/economía , Hipotiroidismo/prevención & control , Recién Nacido , Fenilcetonurias/economía , Fenilcetonurias/prevención & control , Deficiencia de alfa 1-Antitripsina/economía , Deficiencia de alfa 1-Antitripsina/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA